menu search

PCVX / Vaxcyte, Inc. (PCVX) Q4 2022 Earnings Call Transcript

Vaxcyte, Inc. (PCVX) Q4 2022 Earnings Call Transcript
Vaxcyte, Inc. (NASDAQ:PCVX ) Q4 2022 Earnings Conference Call February 27, 2023 4:30 PM ET Company Participants Andrew Guggenhime - President and Chief Financial Officer Grant Pickering - Chief Executive Officer Jim Wassil - Executive Vice President and Chief Operating Officer Jeff Fairman - Vice President, Research Conference Call Participants Jason Gerberry - Bank of America Roger Song - Jefferies David Risinger - SVB Seamus Fernandez - Guggenheim. Jonathan Miller - Evercore Louise Chen - Cantor Joseph Stringer - Needham Operator Good afternoon. Read More
Posted: Feb 27 2023, 22:03
Author Name: Seeking Alpha
Views: 103110

PCVX News  

Strong Financials And Pipeline Position Vaxcyte For Success

By Seeking Alpha
August 17, 2023

Strong Financials And Pipeline Position Vaxcyte For Success

Vaxcyte, Inc. is a clinical-stage vaccine company developing high-fidelity vaccines for bacterial diseases. The company's Q2 2023 earnings report show more_horizontal

Wall Street Analysts Think Vaxcyte, Inc. (PCVX) Could Surge 33.33%: Read This Before Placing a Bet

By Zacks Investment Research
May 29, 2023

Wall Street Analysts Think Vaxcyte, Inc. (PCVX) Could Surge 33.33%: Read This Before Placing a Bet

The average of price targets set by Wall Street analysts indicates a potential upside of 33.3% in Vaxcyte, Inc. (PCVX). While the effectiveness of thi more_horizontal

Vaxcyte: Positive Phase 2 Results Elevate Confidence In VAX-24's Potential

By Seeking Alpha
May 17, 2023

Vaxcyte: Positive Phase 2 Results Elevate Confidence In VAX-24's Potential

Vaxcyte is emerging as a leader in vaccine innovation, leveraging high-fidelity vaccines to combat bacterial diseases. The company's lead candidate, V more_horizontal

Vaxcyte (PCVX) Up on Pneumococcal Conjugate Vaccine Data

By Zacks Investment Research
April 18, 2023

Vaxcyte (PCVX) Up on Pneumococcal Conjugate Vaccine Data

Vaxcyte (PCVX) announces positive results from the mid-stage study of its 24-Valent pneumococcal conjugate vaccine candidate, VAX-24, in adults aged 6 more_horizontal

Still 50% Upside To Go, Wall Street Is Getting Vaxcyte Right

By MarketBeat
April 18, 2023

Still 50% Upside To Go, Wall Street Is Getting Vaxcyte Right

When SVB Securities analyst David Risinger reiterated his bullish opinion on Vaxcyte, Inc. (NASDAQ: PCVX) last week, few investors noticed. The stock more_horizontal

Vaxcyte to Host Webcast and Conference Call to Discuss Results from Phase 2 Study of its 24-Valent Pneumococcal Conjugate Vaccine Candidate in Adults Aged 65 and Older and Full Six-Month Safety Data f

By GlobeNewsWire
April 16, 2023

Vaxcyte to Host Webcast and Conference Call to Discuss Results from Phase 2 Study of its 24-Valent Pneumococcal Conjugate Vaccine Candidate in Adults Aged 65 and Older and Full Six-Month Safety Data f

SAN CARLOS, Calif., April 16, 2023 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fide more_horizontal

Vaxcyte to Host Webcast and Conference Call to Discuss Results from Phase 2 Study of its 24-Valent Pneumococcal Conjugate Vaccine Candidate in Adults Aged 65 and Older and Full Six-Month Safety Data f

By GlobeNewsWire
April 16, 2023

Vaxcyte to Host Webcast and Conference Call to Discuss Results from Phase 2 Study of its 24-Valent Pneumococcal Conjugate Vaccine Candidate in Adults Aged 65 and Older and Full Six-Month Safety Data f

SAN CARLOS, Calif., April 16, 2023 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fide more_horizontal

Vaxcyte to Host Webcast and Conference Call to Discuss Results from Phase 2 Study of its 24-Valent Pneumococcal Conjugate Vaccine Candidate in Adults Aged 65 and Older and Full Six-Month Safety Data f

By GlobeNewsWire
April 16, 2023

Vaxcyte to Host Webcast and Conference Call to Discuss Results from Phase 2 Study of its 24-Valent Pneumococcal Conjugate Vaccine Candidate in Adults Aged 65 and Older and Full Six-Month Safety Data f

SAN CARLOS, Calif., April 16, 2023 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fide more_horizontal


Search within

Pages Search Results: